TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Wanbury Limited ( (IN:WANBURY) ) is now available.
Wanbury Limited’s Board of Directors approved the unaudited financial results for the third quarter and nine months ending December 31, 2024, highlighting the company’s financial performance. Additionally, they announced the issuance of senior, secured, unrated, unlisted, redeemable, and non-convertible debentures totaling Rs. 175 crore from Emerging India Credit Opportunities Fund II on a private placement basis, indicating an effort to raise capital for future projects. Furthermore, the company granted 200,000 stock options to employees under its 2016 ESOP plan, aiming to incentivize and retain talent.
More about Wanbury Limited
Wanbury Limited operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical formulations and active pharmaceutical ingredients. The company is engaged in serving both domestic and international markets, with a commitment to providing quality healthcare solutions.
YTD Price Performance: -27.70%
Average Trading Volume: 22,819
Current Market Cap: 7.55B INR
For an in-depth examination of WANBURY stock, go to TipRanks’ Stock Analysis page.